Jobson Medical files for chapter 11 debt relief

Share this article:

Jobson Medical Information Holdings filed for chapter 11 bankruptcy in New York Thursday, the company said, part of an effort to amend and extend its credit and strengthen its balance sheet

The closely held company, which is backed by private equity firm Wicks Group, said lenders have already approved its plan and that it expects to emerge from the “pre-packaged” Chapter 11 process in about 30 to 40 days.

“This credit agreement will provide us with the flexibility needed to continue our growth,” said Jeff MacDonald, CEO of Jobson Medical Information Holdings. “JMIH is a very strong and profitable business and will continue to operate.”

In 2005 Jobson Medical Information Holdings bought medical imprint Jobson Publishing for an undisclosed sum. Titles include US Pharmacist20/20 and Review of Optometry. Shortly after, it scooped up med-ed firm DesignWrite. JMIH also controls accredited CME provider Postgraduate Institute for Medicine, as well as information services /alert Marketing and Frames Data.

According to a Bloomberg report, JMIH listed assets and debt of as much as $500 million each in its chapter 11 petition, and 16 affiliates also sought court protection.

The company is one of several B2B magazine operators that have refinanced their debt over the last year-and-a-half due to a challenging market, including Hanley Wood (2012), Summit Business Media (2011) and Penton Media (2010).

“Jobson has an excellent stable of assets, and with the economic downturn and the impact upon them, [it] just made their balance sheet untenable,” said Roland DeSilva, managing partner of media banker DeSilva+Phillips.

Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...